Abstract:Background Elevated lipoprotein(a) is a well‐established risk factor for atherosclerotic vascular disease but is not measured in routine clinical care. Screening of high lipoprotein(a) in individuals with moderate elevations of low‐density lipoprotein cholesterol (LDL‐C) may identify individuals at high risk of cardiovascular disease. Methods and Results We examined 2606 Framingham Offspring participants (median age, 54 years; 45% men) prospectively with a median follow‐up of 15 years (n=392 incident cardiovascular events). Individuals with higher (≥100 nmol/L) versus lower lipoprotein(a) were divided into groups based on LDL‐C <135 mg/dL versus ≥135 mg/dL. In Cox models, after adjustment for known risk factors, high lipoprotein(a) (≥100 nmol/L) and LDL‐C ≥135 mg/dL were each significant predictors of cardiovascular disease (LDL‐C ≥135 mg/dL: hazard ratio [HR], 1.34; 95% CI, 1.09–1.64; P =0.006; high lipoprotein (a): HR, 1.31; 95% CI, 1.03–1.66; P =0.026). Across the groups of high/low lipoprotein (a) and LDL‐C ≥135 mg/dL or <135 mg/dL, the absolute cardiovascular disease risks at 15 years were 22.6% (high lipoprotein(a)/LDL‐C ≥135 mg/dL, n=248), 17.3% (low lipoprotein(a)/LDL‐C ≥135 mg/dL, n=758), 12.7% (high lipoprotein(a)/LDL‐C <135 mg/dL, n=275) and 11.5% (low lipoprotein(a)/LDL‐C <135 mg/dL, n=1328, reference group). Among individuals with LDL‐C ≥135 mg/dL, those with high lipoprotein(a) had a 43% higher risk (HR, 1.43; 95% CI, 1.05–1.97; P =0.02). Presence of high lipoprotein(a) with moderate LDL‐C levels (135–159 mg/dL) yielded absolute risks equivalent to those with LDL‐C ≥160 mg/dL (23.5%, 95% CI, 17.4%–31.3%; and 20.7%, 95% CI, 16.8%–25.3%, respectively). Conclusions Concomitant elevation of LDL‐C ≥135 mg/dL and lipoprotein(a) ≥100 nmol/L is associated with a high absolute risk of incident cardiovascular disease. lipoprotein(a) measurement in individuals with moderate elevations in LDL‐C, who do not otherwise meet criteria for statins, may identify individuals at high cardiovascular risk. Nonstandard Abbreviations and Acronyms CARDIoGRAMplusC4D Coronary Artery Disease Genome wide Replication and Meta analysis plus the Coronary Artery Disease Genetics CHARGE Cohorts for Heart and Aging Research in Genomic Epidemiology CVD cardiovascular disease FATS Familial Atherosclerosis Treatment Study FHS Framingham Heart Study LDL‐C low‐density lipoprotein cholesterol NRI net reclassification index Clinical Perspective What Is New? Individuals with both lipoprotein(a) ≥100 nmol/L and low‐density lipoprotein cholesterol ≥135 mg/dL represent a group at higher risk of developing cardiovascular disease. What Are the Clinical Implications? Measuring lipoprotein(a) may help stratify cardiovascular disease risk associated with moderate low‐density lipoprotein cholesterol, identifying individuals who may benefit from statin treatment. Elevated lipoprotein(a) is among the most common genetic dyslipidemias worldwide, affecting 1 in 5 individuals, and is an independent risk factor for cardiovascular disease (CVD). 1 , 2 Although evidence from Mendelian randomization supports a causal role of lipoprotein(a) in CVD, 3 , 4 limited therapeutic options exist to directly lower lipoprotein(a). 5 Current recommended strategies for management of individuals with high lipoprotein(a) emphasize the importance of managing other risk factors, including lowering elevated low‐density lipoprotein cholesterol (LDL‐C) concentrations, without much supporting evidence for such an approach. 6 , 7 , <a class="tab-link" href="# -Abstract Truncated-

Abstract 15650: Relationship Between Lipoprotein (a) and Aortic Vulnerable Plaques Detected by Non-Obstructive General Angioscopy

Association of Lipoprotein (a) With Coronary-Computed Tomography Angiography–Assessed High-Risk Coronary Disease Attributes and Cardiovascular Outcomes

Usefulness of Lipoprotein (a) for predicting progression of non-culprit coronary lesions after acute myocardial infarction

Lipoprotein(a) and Long-Term Plaque Progression, Low-Density Plaque, and Pericoronary Inflammation

Impact of serum lipoprotein (a) level on coronary plaque progression and cardiovascular events in statin-treated patients with acute coronary syndrome: a yokohama-acs substudy

Abstract TP226: Analysis of the Association Between Lipoprotein(a) Levels and Carotid Plaque and Coronary Artery Calcium Using Health Checkup Data

Lipoprotein(a) is associated with necrotic core progression of non-culprit coronary lesions in statin-treated patients with angina pectoris

Coronary atherosclerotic plaque burden and characterization by spectral computed tomography scan in patients with high lipoprotein a and non-hemodynamically significant stenosis

Association between lipoprotein(a) and cardiovascular disease in patients undergoing coronary angiography

Genetically predicted lipoprotein(a) associates with coronary artery plaque severity independent of low-density lipoprotein cholesterol

Lipoprotein(a) Is Associated With the Progression and Vulnerability of New-Onset Carotid Atherosclerotic Plaque

Association Between Lipoprotein(a) and Obstructive Coronary Artery Disease and High-Risk Plaque: Insights From the PROMISE Trial

The association of lipoprotein(a) and intraplaque neovascularization in patients with carotid stenosis: a retrospective study

Association between apolipoprotein B/A1 ratio and coronary plaque vulnerability in patients with atherosclerotic cardiovascular disease: an intravascular optical coherence tomography study

Risks of Incident Cardiovascular Disease Associated With Concomitant Elevations in Lipoprotein(a) and Low-Density Lipoprotein Cholesterol-The Framingham Heart Study.

Association of Lipoprotein(a) Levels With Myocardial Infarction in Patients With Low-Attenuation Plaque

Lipoprotein(a) and Coronary Plaque in Asymptomatic Individuals: The Miami Heart Study at Baptist Health South Florida

Associations between lipoprotein(a), oxidized phospholipids, and extracoronary vascular disease

Lipoprotein(a) is Associated with Increased Low-Density Plaque Volume

Correlation between lipoprotein-associated phospholipase A2 and main risk factors in unstable angina pectoris patients

Association between elevated lipoprotein(a) levels and vulnerability of carotid atherosclerotic plaque: A systematic review.